On May 26, 2020, the NIH announced a new study that provides an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy, and was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status.

In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. The findings were published in the Journal of Clinical Oncology.